Motley Fool Hidden Gems Investing
Motley Fool Hidden Gems Investing

Nov 22, 2026 · 28 min

Compass Pathways bets on supervised psilocybin therapy

The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to Know

FDA approval could determine whether psilocybin becomes a standardized, reimbursed treatment for patients whose depression has resisted existing medicines.

3 key takeaways
  1. 1Compass Pathways is developing synthetic Comp360 psilocybin for supervised treatment of treatment-resistant depression and potentially PTSD.
  2. 2The proposed model relies on preparation, monitored dosing, and post-session integration rather than daily medication.
  3. 3Compass argues that infrequent administrations can support a sustainable business through unmet demand, clinic efficiency, insurance coverage, and intellectual property.

Don't miss

Kabir Nath walks through a supervised dosing session, from preparation and monitoring to music, blindfolds, transportation, and integration.

The brief

Compass Pathways CEO Kabir Nath describes the company’s effort to win FDA approval for medical-grade psilocybin therapy, beginning with treatment-resistant depression and potentially extending to PTSD.

Nath distinguishes synthetic Comp360 from recreational mushrooms, arguing that clinical trials, physician supervision, manufacturing standards, and insurance coverage define a medical treatment model.

A treatment session includes preparation, monitored dosing with music and blindfolds, transportation, and post-session integration; the experience is inward-directed but tightly standardized for safety.

The central business tension is frequency: patients may need only one to three sessions, so Compass must turn rapid, durable benefits and efficient clinic visits into a sustainable model.

Nath frames standardized, insured treatment as complementary to natural-medicine settings while pointing to patents, competition, and esketamine as precedents for a commercial psychedelic market.

What was said on this episode

12 statements · 11 positive · 1 neutral

  1. Kabir Nathon Psilocybin therapyPositive0:09

    Two or three annual psilocybin sessions may relieve depression symptoms for up to a year

    “perhaps two or three day-long sessions in a year can give you relief from depression symptoms for up to a year”

    Listen at 0:09

  2. Kabir Nathon Natural psychedelic medicineNeutral23:23

    Natural psychedelic medicine settings will continue to exist

    “the natural medicine world is going to continue to exist”

    Listen at 23:23

  3. Kabir Nathon Natural psychedelic medicine infrastructure in Oregon and ColoradoPositive23:35

    Natural psychedelic infrastructure will continue developing in Oregon and Colorado

    “I expect to see that continue to develop”

    Listen at 23:35

  4. Kabir Nathon SpravatoPositive24:20

    Spravato is on track for a $3–3.5 billion annualized run rate

    “Spravato is on track to a three, three and a half billion dollar run rate”

    Listen at 24:20

  5. Kabir Nathon psychedelicsPositive25:59

    Psychedelics will develop transformative market potential like immuno-oncology

    “I think you're going to see exactly the same with psychedelics”

    Listen at 25:59

  6. Kabir Nathon Psychedelic treatmentsPositive26:01

    Psychedelic treatments will expand into currently untreated psychiatric conditions

    “you're going to see movement from some of the traditional neuropsych areas, where we've all started, into areas where there is nothing used today”

    Listen at 26:01

  7. Kabir Nathon Psychedelic treatments for OCD, eating disorders, and substance-use disordersPositive26:11

    Potential psychedelic applications include OCD, eating disorders, and substance-use disorders

    “Obsessive compulsive disorder, eating disorders, substance use disorders, and so on”

    Listen at 26:11

  8. Kabir Nathon psychedelicsPositive26:16

    Psychedelics will create a massive commercial opportunity

    “I think this will be a massive opportunity”

    Listen at 26:16

  9. Compass may remain a leader in psychedelic medicine

    “I would hope the Compass continues to be a leader in that field”

    Listen at 26:18

  10. Kabir Nathon Psychedelic treatment centersPositive26:39

    Psychedelic treatment centers will proliferate with varied operating models

    “you will see many, many different treatment centers, a range of different models”

    Listen at 26:39

  11. Kabir Nathon Psychedelic treatment-center infrastructurePositive26:45

    Corporate investment will enter psychedelic treatment-center infrastructure

    “I think you're going to see a lot of corporate money coming into that side”

    Listen at 26:45

  12. Kabir Nathon Treatment-resistant depressionPositive27:01

    Treatment-resistant depression may eventually cease to exist

    “this idea of treatment-resistant depression no longer exists”

    Listen at 27:01

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.

Compass Pathways bets on supervised psilocybin therapy · PodLume